Narenraj Arulprakash
Staff Neurologist
Also affiliated: Johns Hopkins University (2024); Sri Ramachandra Institute of Higher Education and Research (2018); University of Arkansas Medical Center (2020–2024); Johns Hopkins Medicine (2024); Baptist Health Foundation (2020); Parents' Place of Maryland (2020); University of Applied Management Studies (2021); Neurology, Inc (2021)
Staff Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Narenraj Arulprakash's research focuses on the pharmacological effects of antiplatelet medications, particularly ticagrelor and clopidogrel, in patients with chronic kidney disease. His work has investigated the differential impact of these drugs on platelet aggregation and inflammatory markers in individuals with advanced renal insufficiency. Arulprakash also studies neurological complications and outcomes associated with various medical conditions, including COVID-19 and Wernicke's encephalopathy. His publications have examined the underutilization of stroke care and neurocritical care during the COVID-19 pandemic, as well as atypical presentations of neurological disorders. He has also documented cases of immune-related adverse events, such as myasthenia gravis induced by immune checkpoint inhibitors. Arulprakash has a publication record of 12 works, with an h-index of 5 and 82 total citations.
Metrics
- h-index: 5
- Publications: 12
- Citations: 86
Selected Publications
-
Case of Immune Checkpoint Inhibitor Induced Myasthenia Gravis (2024)
-
Atypical Clinical Presentations and Neuroimaging Findings of Wernicke Encephalopathy (P4-4.004) (2023)
-
Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease (2023)
-
Cerebellar restricted diffusion in Wernicke’s encephalopathy (2022)
-
Continued Underutilization of stroke care during the COVID-19 pandemic (2021)
-
Coronavirus Disease 2019 in Patients With Prior Ischemic Stroke (2020)
-
Trends of Industry Payments in Neurology Subspecialties (2020)
Collaboration Network
Top Collaborators
- Continued Underutilization of stroke care during the COVID-19 pandemic
- Cerebellar restricted diffusion in Wernicke’s encephalopathy
- Atypical Clinical Presentations and Neuroimaging Findings of Wernicke Encephalopathy (P4-4.004)
- Continued Underutilization of stroke care during the COVID-19 pandemic
- Continued Underutilization of stroke care during the COVID-19 pandemic
- Continued Underutilization of stroke care during the COVID-19 pandemic
- Continued Underutilization of stroke care during the COVID-19 pandemic
- Continued Underutilization of stroke care during the COVID-19 pandemic
- Continued Underutilization of stroke care during the COVID-19 pandemic
- Continued Underutilization of stroke care during the COVID-19 pandemic
- Continued Underutilization of stroke care during the COVID-19 pandemic
- Continued Underutilization of stroke care during the COVID-19 pandemic
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
Similar Researchers
Based on overlapping research topics